LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

Search

Edwards Lifesciences Corp

Geschlossen

BrancheGesundheitswesen

84.06 -0.78

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

83.96

Max

85.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

-41M

290M

Verkäufe

21M

1.6B

KGV

Branchendurchschnitt

37.167

105.69

Gewinnspanne

18.692

Angestellte

15,800

EBITDA

-13M

388M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+9.69% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.3B

50B

Vorheriger Eröffnungskurs

84.84

Vorheriger Schlusskurs

84.06

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Edwards Lifesciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Aug. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

Peer-Vergleich

Kursveränderung

Edwards Lifesciences Corp Prognose

Kursziel

By TipRanks

9.69% Vorteil

12-Monats-Prognose

Durchschnitt 92.95 USD  9.69%

Hoch 104 USD

Tief 83 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Edwards Lifesciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

24 ratings

14

Buy

10

Halten

0

Sell

Technischer Score

By Trading Central

74.52 / 75.54Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat